The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy

By Elmer Lawrence W   Bertoni John M  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 16, 2008-11 ,pp. : 2759-2772

Informa Healthcare

Access to resources Recommend Favorite

Monoamine Oxidase B Inhibitors in Parkinson's Disease

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 16, Iss. 4, 2017-07 ,pp. : 425-439

Bentham Science Publishers

Access to resources Recommend Favorite

Monoamine Oxidase B Inhibitors for the Treatment of Parkinson's Disease: A Review of Symptomatic and Potential Disease-Modifying Effects

By Schapira Anthony H.V.  

CNS Drugs, Vol. 25, Iss. 12, 2011-12 ,pp. : 1061-1071

Adis International

Access to resources Recommend Favorite

Monoamine oxidase A and B inhibitors

By Jegham S.   George P.  

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 9, 1998-09 ,pp. : 1143-1150

Informa Healthcare

Access to resources Recommend Favorite

Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase

By Naoi M.   Maruyama W.   Youdim M. B. H.   Yu P.   Boulton A. A.  

Inflammopharmacology, Vol. 11, Iss. 2, 2003-06 ,pp. : 175-181

VSP

Access to resources Recommend Favorite